Company overview
ScaleReady is a strategic partnership providing scalable and cost-effective closed workflow solutions for immune cell therapy manufacturing. The platform integrates GMP cytokines, gene engineering capabilities, and G-Rex bioreactors to enable linear process scaling from development to commercial production. ScaleReady addresses manufacturing complexity by automating unit operations, reducing skilled personnel requirements, and supporting addressable patient populations of 30,000+ patients annually.
ScaleReady is listed in the NovaPharmaNews Supplier Hub as a CDMO & Manufacturing partner serving United States & Americas. Core focus areas include cell therapy manufacturing, immune cell production, bioreactor technology, gmp cytokines, scalable manufacturing platform.
Industry categories: CDMO & Manufacturing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with ScaleReady include Bioreactor — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://www.bio-techne.com/research-areas/immune-cell-therapy/scaleready
- Categories
- CDMO & Manufacturing
- Markets served
- United States & Americas
- Keywords
- cell therapy manufacturing, immune cell production, bioreactor technology, gmp cytokines, scalable manufacturing platform
Products & technologies
Therapeutic areas
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What technologies does ScaleReady integrate into its manufacturing platform?
- ScaleReady combines GMP cytokines, gene engineering tools, and G-Rex bioreactors within a closed workflow system designed for intelligent and intentional cell therapy manufacturing.
- How does ScaleReady support process scaling from development to commercial production?
- The platform enables linear scaling, allowing rapid process development at small scale with protocols that predictably scale up and out. This linear model provides transparency for modeling and visibility of scaling requirements needed to meet future patient populations.
- What are the key operational benefits of using ScaleReady's approach?
- ScaleReady reduces process complexity and personnel requirements through automated unit operations and G-Rex bioreactor design, which eliminates unnecessary process interventions while increasing repeatability and cost-effectiveness.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
